About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The Microbiology research group of the Vall d'Hebron Research Institute (VHIR) focuses on the study of microbiological aspects —in basic, translational and clinical research— that could improve the outcome of patients with infectious diseases.
Our priority research areas are:
We actively collaborate with other microbiology laboratories, health services, national and international centres and organizations, as well as with the different research networks of the Carlos III Health Institute in Spain.
In addition, we carry out an important activity in the surveillance of the genotypic and phenotypic evolution of microorganisms present in the community in terms of their virulence, transmissibility, antigenic escape and antimicrobial resistance, in collaboration with public administrations, both at the national and international level.
IP: Susana Otero Romero Collaborators: Juliana Esperalba Esquerra, Estudio de comorbilidad y de inmunogenicidad vacunal en una cohorte prospectiva de pacientes con primeros brotes sugestivos de E, Laia Pinos Tella, Luciana Midaglia Fernandez, Sonia Maria Uriona Tuma, Sonia Maria Uriona Tuma Funding agency: Instituto de Salud Carlos III Funding: 105270 Reference: PI19/01606 Duration: 01/01/2020 - 30/06/2024
IP: Adrián Sánchez Montalvá Collaborators: Maria Luisa Aznar Ruiz de Alegria, Mª Teresa Tórtola Fernández, Juan Espinosa Pereiro Funding agency: Instituto de Salud Carlos III Funding: 187550 Reference: PI20/01378 Duration: 01/01/2021 - 30/06/2025
IP: Joan Joseph Munné Collaborators: Vicente Descalzo Jorro Funding agency: Instituto de Salud Carlos III Funding: 147620 Reference: PI20/00217 Duration: 01/01/2021 - 30/06/2025
IP: Israel Molina Romero Collaborators: Maria Luisa Aznar Ruiz de Alegria, Elena del Carmen Trigo Esteban, Bibiana Planas Ribas, Marta Sanchiz Cruz, Marc Molins Masdefiol, Esperanza Esteban Serna, Josep Roca Grande, Jose Cabral Jamba , Tayná Marques Torres Barboza Funding agency: EUROPEAN COMMISSION Funding: 3004510.89 Reference: CRESCER_EUROPEAID2019_ Duration: 15/02/2021 - 15/07/2026
The technology could help make stool sample screening more comprehensive and facilitate the identification of parasitic findings for subsequent expert review.
The initiative focuses on awareness, prevention, and the normalization of sexual health check-ups among young people.
All patients showed a favorable clinical course and responded well to antibiotic treatment, without complications.
